A Double-Blind, Placebo-Controlled, Multicenter, Randomized Study Evaluating the Prophylactic Use of Pegfilgrastim on the Incidence of Febrile Neutropenia in Subjects With Advanced Breast Cancer Treated With Single Agent Docetaxel
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention
Proportion of subjects developing febrile neutropenia
Through 4 cycles
No
MD
Study Director
Amgen
United States: Food and Drug Administration
20010144
NCT00035594
February 2002
June 2004
Name | Location |
---|